Skip to content
Screener

ADC Therapeutics ADCT Q1 2026 earnings

Reported May 4, 2026 · Before market open

Revenue$20.9MBeat by $864.2K
EPS-$0.21Miss by $0.02
Revenue estimate$20.0M
EPS estimate-$0.19

Next report

Nov 10, 2026 (in 2 months)
Revenue estimate$18.4M
EPS estimate-$0.21

FAQ

When did ADC Therapeutics report Q1 2026 earnings?
ADC Therapeutics (ADCT) reported Q1 2026 earnings on May 4, 2026 before market open.
What were ADC Therapeutics's Q1 2026 revenue and EPS?
ADC Therapeutics reported revenue of $20.9M and eps of $-0.21 for Q1 2026.
Did ADC Therapeutics beat estimates in Q1 2026?
Revenue beat the consensus estimate of $20.0M by $864.2K. EPS missed the consensus estimate of $-0.19 by $0.02.
How did ADC Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 9.5% from $23.0M a year earlier and eps grew 41.7% from $-0.36.
Where can I find ADC Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-029524) and the 10-Q periodic report (0001628280-26-029819) directly on SEC EDGAR. The filing index links above go to sec.gov.